Professional Documents
Culture Documents
FASENRA - PFS To Pen Communication Downloadable PDF
FASENRA - PFS To Pen Communication Downloadable PDF
FASENRA - PFS To Pen Communication Downloadable PDF
1 2 3
To begin, you need to submit a new prescription for FASENRA Pen. Access 360
can offer support through the complete referral process: simply submit the
Access 360 enrollment form, or submit the prescription directly to the patient’s
Specialty Pharmacy.
• Access 360 can provide assistance in performing a Benefit Investigation, including both Pharmacy
and Medical benefits, and will inform you/your office of any Prior Authorization requirements for your
patient(s) insurance
• The pharmacy that fulfills FASENRA Pen may not be the same pharmacy that fulfills FASENRA prefilled
syringe. Access 360 can also assist with triaging your referral to the appropriate network pharmacy
1 2 3
Once the Benefit Investigation is complete, you/your office will submit a Prior
Authorization to your patient’s insurance.
• Access 360 can provide Prior Authorization support
• CoverMyMeds is another option that you or your office may already be familiar with and comfortable using
2 3 Upon receiving insurance approval, the designated Specialty Pharmacy will contact
the patient directly to obtain consent and will ship FASENRA Pen directly to your
patient’s home. Patients/caregivers may inject after proper training in subcutaneous
injection technique, and after a healthcare professional determines it is appropriate.
• If you experience a delay in insurance approval, please contact Access 360 for more information
about this program
For any questions regarding the process of submitting a new FASENRA prescription
for your patient(s), please contact Access 360 for assistance at 1-833-360-HELP
Access360@AstraZeneca.com One MedImmune Way, Gaithersburg, MD 20878 US-39218 Last Updated 4/20
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to benralizumab or excipients.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥ 5%) include headache and pharyngitis.
Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients
treated with placebo.
INDICATION
FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
• FASENRA is not indicated for treatment of other eosinophilic conditions
• FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus
FASENRA and FASENRA Pen are registered trademarks of the AstraZeneca group of companies.
©2020 AstraZeneca. All rights reserved.
US-39218 Last Updated 4/20